Boosting immunity after CAR-T therapy
Part of Immune system & allergy clinical trials.
This trial checks if giving vaccines after CAR-T cell therapy can help your immune system fight off preventable diseases. It is for adults with certain blood cancers who are about to get CAR-T treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a B-cell blood cancer like certain types of leukemia, lymphoma, or multiple myeloma.
- You are scheduled to receive CAR-T cell therapy soon.
- You have not had CAR-T therapy before.
- You agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This Phase 1 study tests a customized immune-cell treatment (CAR T-cells) plus a vaccine given after stem cell transplant for certain aggressive B-cell non-Hodgkin lymphomas. It aims to help your immune system better recognize and attack the lymphoma and to see how safe the approach is.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
This study tracks infections in people who receive CAR-T cell therapy for certain blood cancers like multiple myeloma and B-cell non-Hodgkin lymphoma. It aims to understand how often infections happen and how to prevent them.
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Hear when a new Vaccine Immunity in CAR-T Cell Therapy Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.